Pharmaceutical company defense lawyers have scored several recent victories in securities class actions in Boston federal court, but a pending U.S. Supreme Court case about the criteria for complaints in securities cases could expose the industry to a new round of securities litigation.
Several dozen cases against about one dozen pharmaceutical companies have clogged Boston’s federal docket during the past four years, but recent defense victories have thinned the ranks of pending consolidated class actions.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
For questions call 1-877-256-2472 or contact us at [email protected]